Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery

The purpose of this study is to determine if the use of propofol only to achieve procedural sedation for the removal of third molars is both safe and effective.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Removal of third molars is a common procedure performed in North America. Many surgeon choose to complete the procedure using procedural sedation. The most commonly used combination of medications to achieve procedural sedation consists of midazolam, fentanyl, and propofol. Propofol has been gaining increasing attention as a sedative agent due to its predictable pharmacokinetics and favorable amnestic properties. These properties make propofol an attractive sedative agent when compared to the benzodiazepines which are known to have a slower onset coupled with a much longer offset resulting in a prolonged sedative effect well beyond that required for completion of the procedure. Several studies have compared the use of propofol in combination with other sedatives with various control groups. These studies reliably confirm both the safety and efficacy of propofol. Some researches have speculated that the differences in nausea and vomiting reported by patients are secondary to the differences in dosage of fentanyl between groups. Others have concluded that fentanyl provides no advantage when using intermittent propofol in short duration procedures. Recent studies have found favourable results when using propofol only to achieve procedural sedation. On review of the Oral and Maxillofacial Surgery literature regarding this topic, a lack of internally and externally validated research was discovered. Oral and Maxillofacial surgical procedures are unique in duration of procedure and use of local anesthesia making it difficult to generalize data obtained from other specialties.

All eligible patients will be assigned to a single group. They will be asked to fill out a survey to determine their level of anxiety prior to the procedure. Participants will then proceed the same as non-study patients to see the nurse for a pre-operative assessment. After seeing the nurse, patients will see the surgeon for the procedure. Most of the data (blood pressure, heart rate, breathing rate etc.) is collected during the procedure. During procedural sedation monitoring is performed as usual but study patients will have capnometry added to the standard of care. Capnometry is a way of examining your breathing. It is the measurement of the carbon dioxide in the air that you breathe out through you nose. After the procedure is complete patients are transported to recovery where they must remain for a minimum of 30 minutes prior to discharge. The nurse in recovery will monitor you recovery continuously during your stay. The nurse will also apply a standard recovery score to your recovery every 5 minutes to track your progression. Once you are recovered from the procedural sedation you will be asked to complete a short questionnaire about your procedural sedation experience. After discharge patients will be contacted by phone 24 to 48 hours later to review a final questionnaire.

Study Type

Interventional

Enrollment (Anticipated)

169

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ben Davis, DDS FRCD(C)
  • Phone Number: 902 473 2070
  • Email: bdavis@dal.ca

Study Contact Backup

  • Name: James Brady, DDS BSc
  • Phone Number: 902 473 7914
  • Email: jrbrady@dal.ca

Study Locations

    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Atlantic Centre for Oral and Maxillofacial Surgery 1278 Tower Rd.
        • Contact:
          • Ben Davis, DDS FRCD(C)
          • Phone Number: 902 473 2070
          • Email: bdavis@dal.ca
        • Contact:
        • Principal Investigator:
          • Ben Davis, DDS FRCD(C)
        • Sub-Investigator:
          • James Brady, DDS BSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • ASA Class I and II patients between the ages of 16 to 50 years scheduled to have their third molars extracted under intravenous sedation.

Exclusion Criteria:

  • history of psychiatric illness, chronic use of central nervous system depressants or antidepressants, or alcohol abuse, had an active infection with systemic symptoms, were morbidly obese, were pregnant, or had a positive history of anesthetic-related complications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Propofol sedation
Patients will be undergo procedural sedation using propofol.
Procedural sedation will be achieved using propofol
Other Names:
  • Diprivan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pre-Sedation Behavioral Sate
Time Frame: Pre-operative assessment by RN the day of surgery just prior to entering the operating room.
Patient will complete Corah anxiety scale.
Pre-operative assessment by RN the day of surgery just prior to entering the operating room.
Efficacy of Sedation
Time Frame: Monitored using a post-operative questionnaire administered 30 minutes after arrival to the recovery room.
The patient does not have unpleasant recall of the procedure.
Monitored using a post-operative questionnaire administered 30 minutes after arrival to the recovery room.
Adverse outcome
Time Frame: Throughout the procedural sedation in a continuous fashion. The start time of the procedural sedation will be defined as the time of the first dose of propofol and the stop time will be the time that the patient is transferred to recovery.
Patient will be monitored for: apnea, aspiration, vomiting, cardiovascular events, excitatory movements, paradoxical response
Throughout the procedural sedation in a continuous fashion. The start time of the procedural sedation will be defined as the time of the first dose of propofol and the stop time will be the time that the patient is transferred to recovery.
Adverse outcomes
Time Frame: The patient will be monitored the recovery room in a continuous fashion for 30 minutes.
Unpleasant recovery reactions, permanent complications.
The patient will be monitored the recovery room in a continuous fashion for 30 minutes.
Patient Satisfaction
Time Frame: This will be measured 30 minutes after arrival to the recovery room and then once again via phone questionnaire between 24 to 48 hours after discharge.
A questionnaire will be given to the patient to complete just prior to discharge. The patient will be contacted 24 to 48 hours after discharge to complete a second questionnaire.
This will be measured 30 minutes after arrival to the recovery room and then once again via phone questionnaire between 24 to 48 hours after discharge.
Level of sedation
Time Frame: This will be measured every 5 minutes throughout the duration of the procedural sedation.
The Ramsay sedation scale will be used to grade the depth of sedation during the procedure.
This will be measured every 5 minutes throughout the duration of the procedural sedation.
Surgeon satisfaction
Time Frame: Immediately after completing the surgical procedure.
The surgeon will complete a 5 point likert scale to determine their level of satisfaction.
Immediately after completing the surgical procedure.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ben Davis, DDS FRCD(C), Staff Surgeon at "Atlantic Centre for Oral and Maxillofacial Surgery"

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Anticipated)

January 1, 2013

Study Completion (Anticipated)

January 1, 2013

Study Registration Dates

First Submitted

October 16, 2010

First Submitted That Met QC Criteria

October 21, 2010

First Posted (Estimate)

October 25, 2010

Study Record Updates

Last Update Posted (Estimate)

October 25, 2010

Last Update Submitted That Met QC Criteria

October 21, 2010

Last Verified

October 1, 2010

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Propofol

Clinical Trials on Propofol

3
Subscribe